Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02785952
Title Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Southwest Oncology Group
Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.